

7S Chan Tsz Wa 7S Li Wing Tung

Drug Development Ibuprofen

Introduction

- an anti-inflammatory drug
- NSAID
- possesses pain-relieving and fever-reducing properties
- particular use in pain relief from arthritis



Introduction (cont'd)

• 2D Structure of Ibuprofen



• 3D Structure of Ibuprofen





Arachidonic acid

Prostaglandin



developed and discovered as a drug by the Boots Company.



2-methylpropylbenzene

Timeline





□ The discovery was made.

- □ anti-inflammatory drugs
- simple screening test for new chemical compounds

□ Research was started.

Aspirin and phenylbutazone were available.
Objective:
1.To develop a drug to treat rheumatoid arthritis (inflamed joints)
2.To have a superior profile both in terms of potency and toxicity to these two drugs.

Timeline (cont'd)



Timeline (cont'd)



Organic synthesis

• A) The original Boots synthesis of ibuprofen



Step1 Friedel-Crafts acetylation of 2-methylpropylbenzene Step2

Reaction with ethyl chloroacetate (Darzens reaction) gave the α , β -epoxy ester

• A) The original Boots synthesis of ibuprofen



 $\frac{\text{Step3}}{\text{The } \alpha, \beta \text{-epoxy ester was}}$ $\frac{\text{decarboxylated and}}{\text{hydrolyzed} \text{ to the aldehyde.}}$

<u>Step4</u> Reaction with hydroxylamine gave the oxime

• A) The original Boots synthesis of ibuprofen



Step5 Then convert to the nitrile

• A) The original Boots synthesis of ibuprofen





• B) The advanced 'green' synthesis of ibuprofen



Formulation Development

 the dose of ibuprofen contained in a normal strength tablet is 200 mg (0.2 g)



Formulation Development

Component	Function	Location
Ibuprofen	Active ingredient	Core
Croscarmellose sodium	Disintegrant	Core
Stearic acid	Lubricant	Core
Sodium laurylsulfate	Lubricant	Core
Sodium citrate	Buffering agent	Core
Colloidal anhydrous silica	Anticaking agent	Core
Carmellose sodium	Coating agent	Coat
Carnuba wax powder	Coating agent	Coat
Calcium sulfate dihydrate	Diluent	Coat
Acacia spray dried	Binding agent	Coat
Sucrose	Binding agent	Coat
Titanium dioxide	Pigment	Coat
Purified water	Diluent	Coat

Safety Test



(I)Pre-clinical testing

• Experiment is carried out with cats and rats.

Findings

- no effect on the cardiovascular system
- did not affect the arterial pressure, frequency and strength of cardiac contractions

Safety Test (cont'd)

(I)Pre-clinical testing

Examinations of the EEG of cats and rabbits

Findings

- no departures from the normal whatsoever following administration of the drug
- no effect on the spasmogenic effects of

Safety Test (cont'd)

(II) Human trials

has undergone extensive clinical trials

Findings:

- possess high therapeutic activity
- improvement in the general condition
- reduction in joint pain, morning stiffness, swelling of the joints, etc.

Approval for marketing

- approved by the FDA in 1974
- approved for sale in the US and other states and its treatment considered effective



Approval for marketing (cont'd)

- relieve pains of bones and muscles
- as a painkiller for inflammation
- recommended dose is 600-1200 mg daily

In acute conditions

increase the daily dose to 1600 mg

**great care in patients suffering from bronchial asthma

